Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
116505622 | 11650562 | 2 | F | 2011 | 20160802 | 20151021 | 20160808 | EXP | US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2015-BI-54324PF | BOEHRINGER INGELHEIM | 0.00 | F | Y | 79.38000 | KG | 20160808 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
116505622 | 11650562 | 1 | PS | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Respiratory (inhalation) | 18 MCG | U | 21395 | 18 | UG | INHALATION POWDER, HARD CAPSULE | QD | |||||
116505622 | 11650562 | 2 | SS | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | Respiratory (inhalation) | 36 MCG | U | 21395 | 18 | UG | INHALATION POWDER, HARD CAPSULE | BID | |||||
116505622 | 11650562 | 3 | C | REVATIO | SILDENAFIL CITRATE | 1 | Oral | 60 MG | 0 | 20 | MG | TABLET | TID | ||||||
116505622 | 11650562 | 4 | C | REVATIO | SILDENAFIL CITRATE | 1 | 0 | ||||||||||||
116505622 | 11650562 | 5 | C | HYDROCODONE | HYDROCODONE | 1 | Unknown | 6 ANZ | 0 | Q4H | |||||||||
116505622 | 11650562 | 6 | C | HYDROCODONE | HYDROCODONE | 1 | Unknown | 120 MG | 0 | 10 | MG | Q2H | |||||||
116505622 | 11650562 | 7 | C | TYLENOL | ACETAMINOPHEN | 1 | Unknown | 6 ANZ | 0 | Q4H | |||||||||
116505622 | 11650562 | 8 | C | PREDNISONE. | PREDNISONE | 1 | Oral | 10 MG | 0 | 10 | MG | TABLET | QD | ||||||
116505622 | 11650562 | 9 | C | PREDNISONE. | PREDNISONE | 1 | 0 | ||||||||||||
116505622 | 11650562 | 10 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | Oral | 60 MG | 0 | 60 | MG | QD | |||||||
116505622 | 11650562 | 11 | C | CLONIDINE HCL | CLONIDINE HYDROCHLORIDE | 1 | Oral | 0.3 MG | 0 | .1 | MG | TABLET | TID | ||||||
116505622 | 11650562 | 12 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | 40 MG | 0 | 40 | MG | TABLET | QD | ||||||
116505622 | 11650562 | 13 | C | PROAIR HFA | ALBUTEROL SULFATE | 1 | Unknown | 12 PUF | 0 | INHALATION SOLUTION | Q4H | ||||||||
116505622 | 11650562 | 14 | C | LASIX | FUROSEMIDE | 1 | Oral | 80 MG | 0 | 40 | MG | TABLET | BID | ||||||
116505622 | 11650562 | 15 | C | KLORCON KDUR | 2 | Oral | 10 MEQ | 0 | 10 | MEQ | TABLET | QD | |||||||
116505622 | 11650562 | 16 | C | PROCARDIA | NIFEDIPINE | 1 | Oral | 60 MG | 0 | 60 | MG | TABLET | QD | ||||||
116505622 | 11650562 | 17 | C | ZELIRIS | 2 | Oral | 500 MCG | 0 | 500 | UG | TABLET | QD | |||||||
116505622 | 11650562 | 18 | C | COLACE | DOCUSATE SODIUM | 1 | Oral | 60 MG | 0 | 60 | MG | CAPSULE | QD | ||||||
116505622 | 11650562 | 19 | C | COLACE | DOCUSATE SODIUM | 1 | Unknown | 200 MG | 0 | 100 | MG | BID | |||||||
116505622 | 11650562 | 20 | C | NORMODYNE | LABETALOL HYDROCHLORIDE | 1 | Unknown | 400 MG | 0 | 100 | MG | TABLET | |||||||
116505622 | 11650562 | 21 | C | ALDACTONE | SPIRONOLACTONE | 1 | Oral | 25 MG | 0 | 25 | MG | TABLET | QD | ||||||
116505622 | 11650562 | 22 | C | IRON | IRON | 1 | Oral | 325 MG | 0 | 325 | MG | TABLET | QD | ||||||
116505622 | 11650562 | 23 | C | ADVAIR DISKUS | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | Unknown | FORMULATION: INHALER; DOSE PER APPLICATION: 250-50MCG PER DOSE INHALER | 0 | BID | |||||||||
116505622 | 11650562 | 24 | C | ALBUTEROL. | ALBUTEROL | 1 | Unknown | 15 MG | 0 | 2.5 | MG | Q4H | |||||||
116505622 | 11650562 | 25 | C | CALCIUM-VIT D | 2 | Oral | 2 ANZ | 0 | TABLET | QD | |||||||||
116505622 | 11650562 | 26 | C | CALCIUM-VIT D | 2 | 0 | |||||||||||||
116505622 | 11650562 | 27 | C | CALCIUM-VIT D | 2 | 0 | |||||||||||||
116505622 | 11650562 | 28 | C | BABY ASPIRIN | ASPIRIN | 1 | Oral | 81 MG | 0 | 81 | MG | TABLET | QD | ||||||
116505622 | 11650562 | 29 | C | KLONOPIN | CLONAZEPAM | 1 | Oral | 0.5 MG | 0 | 1 | MG | TABLET | QOD | ||||||
116505622 | 11650562 | 30 | C | KLONOPIN | CLONAZEPAM | 1 | Oral | 3 MG | 0 | 1 | MG | TABLET | TID | ||||||
116505622 | 11650562 | 31 | C | POTASSIUM CHLORIDE. | POTASSIUM CHLORIDE | 1 | Unknown | 10 MEQ | 0 | 10 | MEQ | TABLET | QD | ||||||
116505622 | 11650562 | 32 | C | DALIRESP | ROFLUMILAST | 1 | Unknown | 500 MCG | 0 | 500 | UG | QD | |||||||
116505622 | 11650562 | 33 | C | LABETALOL | LABETALOLLABETALOL HYDROCHLORIDE | 1 | Unknown | 4 ANZ | 0 | TABLET | Q12H |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
116505622 | 11650562 | 1 | Chronic obstructive pulmonary disease |
116505622 | 11650562 | 3 | Lung disorder |
116505622 | 11650562 | 4 | Pulmonary hypertension |
116505622 | 11650562 | 5 | Arthritis |
116505622 | 11650562 | 6 | Pain |
116505622 | 11650562 | 7 | Arthritis |
116505622 | 11650562 | 8 | Dyspnoea |
116505622 | 11650562 | 9 | Prophylaxis |
116505622 | 11650562 | 10 | Musculoskeletal discomfort |
116505622 | 11650562 | 11 | Dyspnoea |
116505622 | 11650562 | 12 | Blood cholesterol |
116505622 | 11650562 | 13 | Dyspnoea |
116505622 | 11650562 | 14 | Fluid retention |
116505622 | 11650562 | 15 | Blood potassium decreased |
116505622 | 11650562 | 16 | Cardiac disorder |
116505622 | 11650562 | 17 | Dyspnoea |
116505622 | 11650562 | 18 | Cardiac disorder |
116505622 | 11650562 | 19 | Constipation |
116505622 | 11650562 | 20 | Blood pressure measurement |
116505622 | 11650562 | 21 | Dyspnoea |
116505622 | 11650562 | 22 | Blood iron decreased |
116505622 | 11650562 | 23 | Dyspnoea |
116505622 | 11650562 | 24 | Dyspnoea |
116505622 | 11650562 | 25 | Bone disorder |
116505622 | 11650562 | 26 | Vitamin D decreased |
116505622 | 11650562 | 27 | Blood calcium decreased |
116505622 | 11650562 | 28 | Cardiovascular disorder |
116505622 | 11650562 | 29 | Nervousness |
116505622 | 11650562 | 31 | Blood potassium decreased |
116505622 | 11650562 | 32 | Renal disorder |
116505622 | 11650562 | 33 | Cardiac disorder |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
116505622 | 11650562 | DE |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
116505622 | 11650562 | Abasia | |
116505622 | 11650562 | Chronic obstructive pulmonary disease | |
116505622 | 11650562 | Condition aggravated | |
116505622 | 11650562 | Constipation | |
116505622 | 11650562 | Dyspnoea | |
116505622 | 11650562 | Malaise | |
116505622 | 11650562 | Peripheral swelling |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
116505622 | 11650562 | 2 | 2012 | 0 | ||
116505622 | 11650562 | 3 | 201101 | 0 | ||
116505622 | 11650562 | 5 | 2012 | 0 | ||
116505622 | 11650562 | 7 | 2012 | 0 | ||
116505622 | 11650562 | 10 | 2013 | 0 | ||
116505622 | 11650562 | 12 | 2011 | 0 | ||
116505622 | 11650562 | 13 | 2012 | 0 | ||
116505622 | 11650562 | 14 | 2011 | 0 | ||
116505622 | 11650562 | 16 | 2013 | 0 | ||
116505622 | 11650562 | 19 | 2013 | 0 | ||
116505622 | 11650562 | 21 | 2014 | 0 | ||
116505622 | 11650562 | 22 | 2012 | 0 | ||
116505622 | 11650562 | 23 | 2011 | 0 | ||
116505622 | 11650562 | 24 | 2011 | 0 | ||
116505622 | 11650562 | 28 | 2008 | 0 | ||
116505622 | 11650562 | 29 | 2012 | 0 | ||
116505622 | 11650562 | 30 | 2012 | 0 | ||
116505622 | 11650562 | 31 | 2013 | 0 | ||
116505622 | 11650562 | 32 | 2014 | 0 | ||
116505622 | 11650562 | 33 | 2014 | 0 |